RADIATION-HYGIENIC JUSTIFICATION OF OUTPATIENT RADIONUCLIDE THERAPY
Abstract
The possibility of the use of the different therapeutic radiopharmaceuticals labeled with one of the 19 β-γ-emitting radionuclides or 6 α-β-γ-emitting radionuclides in the outpatient regime was identified in the estimateinvestigations. A criterion for admissibility of outpatient regime is effective dose of individuals from the population who occasionally or permanently contact the patients after the radiopharmaceutical introduction. Basing on the dose limits established by the Radiation Safety Standard-99/2009, maximal allowable activities of the mentioned radionuclides were calculated for various geometries and exposure scenarios. It is shown that only patients taking radionuclide therapy courses with 111In and 131I have to be hospitalized even in the case of the most conservative exposure conditions.
About the Authors
B. Ja. Narkevich
Institute of Medical Physics and Engineering, Moscow;
Cancer Research Center after N.N. Blokhin of RAMS, Moscow
Russian Federation
Russian Federation
Tel. (499) 324-10-54. E-mail: narvik@yandex.ru
S. V. Shiryaev
Cancer Research Center after N.N. Blokhin of RAMS, Moscow
Russian Federation
Russian Federation
A. N. Klyopov
Institute of Nuclear Power Engineering in National Research Nuclear University MEPhI, Obninsk
Russian Federation
Russian Federation
N. N. Lipanova
Institute of Medical Physics and Engineering, Moscow;
Cancer Research Center after N.N. Blokhin of RAMS, Moscow
Russian Federation
Russian Federation
Yu. V. Lysak
National Research Nuclear University MEPhI, Moscow
Russian Federation
Russian Federation
References
1. Нормы радиационной безопасности (НРБ-99/2009): Санитарные правила и нормативы (СанПиН 2.6.1.2523 – 09): утв. и введены в действие 01.09.2009 г.
2. ICRP. Release of Patients after Therapy with Unsealed Radionuclides. Recommendation of the ICRP Publication 94. // Annals of the ICRP. – 2004. – V. 34, № 2. – 80 p.
3. IAEA Publication 1207. Applying of Radiation Safety Standards in Nuclear Medicine. Safety Reports Series No. 40. – Vienna: IAEA, 2005.
4. Баллонов, М.И. Радиологические критерии выписки пациента из клиники после радионуклидной терапии или брахитерапии с имплантацией закрытых источников / М.И. Баллонов, В.Ю. Голиков, И.А. Звонова // Радиационная гигиена. – 2009. – Т. 2, № 4. – С. 5–9.
5. Наркевич, Б.Я. Уровни облучения отдельных лиц из населения от пациентов с введенными радиофармпрепаратами / Б.Я.Наркевич, Н.П.Зиновьева // Медико-радиологическая и радиационная безопасность. – 2002. – Т. 47, № 1. – С. 27–33.
6. Шишканов, Н.Г. О радиационной безопасности отдельных лиц из населения при общении с пациентами, прошедшими курс радиоиодотерапии / Н.Г. Шишканов, Ю.М. Бакун, Р.А. Розиев // Медикорадиологическая и радиационная безопасность. – 2001. – Т. 46, № 5. – С. 34–46.
7. Чабань, Ю.М. Радиационная безопасность населения при проведении радиойодтерапии / Ю.М. Чабань [и др.]. – М.: Гоэтар-Медиа, 2009. – С. 142–151.
8. Клёпов, А.Н. Применение методов математического моделирования в ядерной медицине / А.Н. Клёпов [и др.]. – Обнинск: СОЦИН, 2006. – 204 с.
9. Гусев, Н.Г. Защита от излучения протяженных источников / Н.Г. Гусев [и др.]. – М.: Госатомиздат, 1961. – 250 с.
10. ICRU Report 57. Conversion Coefficients for Use in Radiological Protection Against External Radiation. – 1998. – 137 p.
11. Машкович, В.П. Защита от ионизирующих излучений : справочник / В.П. Машкович [и др.]. – М.: Энергоатомиздат, 1995. – 496 с.
12. ICRP Publication 107. Nuclear Decay Data for Dosimetric Calculations // Annals of the ICRP. – V. 38, № 3. – P. 7–96.
13. Neves, M. Chemical and biological evaluation of 153Sm and 46/47Sc complexes of indazolebisphosphonates for targeted radiotherapy / М.Neves [et al.] // Appl. Radiat. Isotopes. – 2011. – V. 69, № 1. – P. 80–84.
14. Novak-Hofer, I. Copper-67 as a therapeutic nuclide for radimmunotherapy / I. Novak-Hofer [et al.] // Eur. J. Nucl. Med. Mol. Imaging. – 2002. – V. 29, № 6. – P. 821–830.
15. Lewington, V.J. Bone-seeking radionuclides for therapy / V.J. Lewington // J. Nucl. Med. – 2005. – V. 46, № 1, Suppl. – P. 38S–47S.
16. Fondell, A. Two-step targeting for effective radionuclide therapy. Preclinical evaluation of 125I-labelling anthracycline delivered by tumor targeting liposomes / A. Fondell. – Uppsala Univ., 2011.
17. Gerard, S.K. 131I dosimetry and thyroid stunning / S.K. Gerard [et al.] // J. Nucl. Med. – 2003. – V.44, № 12. – P. 2039–2040.
18. Pinch, C. Radiation synovectomy using 165Dy ferric-hydroxide and oxidative DNA damage in patients with different types of arthritis / C. Pinch [et al.] // J. Nucl. Med. -2000. – V. 41, № 2. – P. 250–257.
19. Valkema, R. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA]octreotide: the Rotterdam experience / R. Valkema [et al.] // Seminars Nucl. Med. – 2002. – V. 32, № 2. – P.110–122.
20. Giralt, S.166Ho-DOTPM plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase ½ trials / S. Giralt [et al.] // Blood. – 2003. – V. 102, № 7. – P. 2684–2691.
21. 170Tm-EDTMP: a potential cost-effective alternative 89SrCl2 for bone pain palliation // Nucl. Med. Biol. – 2009. – V. 36, № 5. – P. 561–568.
22. Ando, A. Study of subcellular distribution of 169Yb and 111In in tumor and liver / A. Ando // Radioisotopes. – 1977. – V. 26, № 3. – P. 169–174.
23. Chakraborty, S.175Yb labeled hydroxyapatite: a potential agent for use in radiation synovectomy of small joints / S. Chakraborty [et al.] // Nucl. Med. Biol. – 2006. – V. 33, № 4. – P. 585–591. 2
24. Bakker, W.H. Practical aspects of peptide receptor radionuclide therapy 177Lu-[DOTA0,Tyr3] octreotat / W.H. Bakker [et al.] // Q. J. Nucl. Med Mol. Imaging. – 2006. – V. 50, № 4. – P. 265–271.
25. Kannan, R. Functionalized radioactive gold nanoparticles in tumor therapy / R. Kannan [et al.] // Nanomedicine and Nanobiotechnology. – 2011. – V. 4, № 1. – P. 42–51.
26. Abrams, P.G. Radioimmunotherapy of Cancer / P.G. Abrams. – NY.: CRC Press. – 2000. – 416 p.
27. Zalutsky, M.R., Targeted α-particle radiotherapy with 211Atlabeled monoclonal antibodies / M.R. Zalutsky[et al.] // Nucl. Med. Biol. – 2007. – V. 34, № 7. – P. 779–785.
28. Miao, Y. Melanoma therapy via peptide-targeted alpharadiation / Y. Miao [et al.] // Clin. Cancer Res. – 2005. – V. 11, № 15. – P. 5615–5621.
29. Yong, K. Towards of 212Pb as a clinical therapeutic; getting the lead in / K. Yong [et al.] // Dalton Trans. – 2011. – V. 40, № 23. – P. 6068–6076.
30. Sartor, O. Targeted use of alpha particles: current status in cancer therapeutics / O. Sartor [et al.] // Nucl. Med. Radiat. Ther. – 2012. – V. 3, № 4.
31. Miederer, M. Realizing the potential of actinium-225 radionuclide generator in targeted alpha-particle therapy application / M. Miederer [et al.] // Adv. drug Deliv. Rev. – 2008. – V. 60, № 12. – P. 1371–1382.
32. Allen, B.J. Systemic targeted alpha radiotherapy for cancer / B.J. Allen // Радиационная онкология и ядерная медицина. – 2013. – № 2. – С. 82–98.
33. Mukhopadhyay, B. Application of the carrier free radioisotopes of second transition series elements in the field of nuclear medicine / B. Mukhopadhyay // J. Nucl. Med. Radiat. Ther. – 2011. – V. 2, № 2. –
34. Hillegonds, D.J. The management of painful bone metastases with an emphasis on radionuclide therapy / D.J. Hillegonds // J. Natl. Med. Assoc. – 2007. – V. 99, № 7. – P. 785–794.
35. Kucuk, O.N. Selective intraarterial radionuclide therapy with 90Y microspheres for unresectable primery and metastatic liver tumors / O.N. Kucuk [et al.] // World J. Surg. Oncol. – 2011. – V. 9, № 1. – P. 86–96.
36. Rajendran, J.G. Therapeutic Radioisotopes / J.G. Rajendran // In: Nuclear Medicine Therapy. Ed. by J.F. Eary, W. Brenner. – N.-Y., London: Informa Healthcare, 2007. – 195 p.
37. Ehrhardt, G.I. A new Cd-115 leads to In-115m radionuclide generator / G.I. Ehrhardt [et al.] // J. Nucl. Med. – 1983. – V. 24, № 4. – P. 342–352.
38. Хабриев, Р.У. Руководство по экспериментальному (доклиническому) изучению новых форм фармакологических веществ / Р.У. Хабриев. – М.: Медицина, 2005.
39. Lubin, E. Definitive improvement in the approach to the treated patient as a radioactive source / E. Lubin // J. Nucl. Med. – 2002. – V. 43. – P. 364–365.
40. Гигиенические требования по обеспечению радиационной безопасности при проведении лучевой терапии с помощью открытых радионуклидных источников. (СанПиН 2.6.1.2368 – 08). – М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2009, 74 с.
41. Основные санитарные правила обеспечения радиационной безопасности (ОСПОРБ-99/2010): СП 2.6.1.2612-10): зарегистрирован 11 августа 2010 г. Регистрационный № 18115. – М.: Минюст России, 2010. – 82 с.
42. Neves, M. Radionuclides used for therapy and suggestion for new candidates / M. Neves // J. Radioanalyt. Nucl. Chem. – 2005. – V. 266. – № 3. – P. 377–384.
Review
For citations:
Narkevich B.J., Shiryaev S.V., Klyopov A.N., Lipanova N.N., Lysak Yu.V. RADIATION-HYGIENIC JUSTIFICATION OF OUTPATIENT RADIONUCLIDE THERAPY. Radiatsionnaya Gygiena = Radiation Hygiene. 2014;7(2):21-29. (In Russ.)
Views:
969
Email this article 